CL2013001402A1 - Un comprimido que comprende a) una primera capa comprendiendo rilpivirina hcl, sustancialmente exenta de fumarato de diisopropilo de tenofovir, b) una segunda capa comprendiendo fumarato de diisopropilo de tenofovir, sustancialmente exenta de rilpivirina hcl, y c) adicionalmente emtricitabina; y su uso para tratar una infeccion por vih. - Google Patents

Un comprimido que comprende a) una primera capa comprendiendo rilpivirina hcl, sustancialmente exenta de fumarato de diisopropilo de tenofovir, b) una segunda capa comprendiendo fumarato de diisopropilo de tenofovir, sustancialmente exenta de rilpivirina hcl, y c) adicionalmente emtricitabina; y su uso para tratar una infeccion por vih.

Info

Publication number
CL2013001402A1
CL2013001402A1 CL2013001402A CL2013001402A CL2013001402A1 CL 2013001402 A1 CL2013001402 A1 CL 2013001402A1 CL 2013001402 A CL2013001402 A CL 2013001402A CL 2013001402 A CL2013001402 A CL 2013001402A CL 2013001402 A1 CL2013001402 A1 CL 2013001402A1
Authority
CL
Chile
Prior art keywords
layer
substantially free
diisopropyl fumarate
rilpivirine hcl
tenofovir
Prior art date
Application number
CL2013001402A
Other languages
English (en)
Spanish (es)
Inventor
Reza Oliyai
Lauren Wiser
Mark Menning
Original Assignee
Gilead Sciences Inc
Janssen R & D Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013001402(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc, Janssen R & D Ireland filed Critical Gilead Sciences Inc
Publication of CL2013001402A1 publication Critical patent/CL2013001402A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2013001402A 2010-11-19 2013-05-17 Un comprimido que comprende a) una primera capa comprendiendo rilpivirina hcl, sustancialmente exenta de fumarato de diisopropilo de tenofovir, b) una segunda capa comprendiendo fumarato de diisopropilo de tenofovir, sustancialmente exenta de rilpivirina hcl, y c) adicionalmente emtricitabina; y su uso para tratar una infeccion por vih. CL2013001402A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41560010P 2010-11-19 2010-11-19

Publications (1)

Publication Number Publication Date
CL2013001402A1 true CL2013001402A1 (es) 2013-12-27

Family

ID=45094284

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013001402A CL2013001402A1 (es) 2010-11-19 2013-05-17 Un comprimido que comprende a) una primera capa comprendiendo rilpivirina hcl, sustancialmente exenta de fumarato de diisopropilo de tenofovir, b) una segunda capa comprendiendo fumarato de diisopropilo de tenofovir, sustancialmente exenta de rilpivirina hcl, y c) adicionalmente emtricitabina; y su uso para tratar una infeccion por vih.

Country Status (36)

Country Link
US (1) US10857102B2 (OSRAM)
EP (2) EP2640362B2 (OSRAM)
JP (2) JP2014500261A (OSRAM)
KR (1) KR101923103B1 (OSRAM)
CN (2) CN103491948B (OSRAM)
AP (1) AP3816A (OSRAM)
AR (2) AR084500A1 (OSRAM)
AU (3) AU2011329642B2 (OSRAM)
BR (1) BR112013012245B1 (OSRAM)
CA (1) CA2818097C (OSRAM)
CL (1) CL2013001402A1 (OSRAM)
CO (1) CO6761300A2 (OSRAM)
CR (1) CR20130293A (OSRAM)
DK (1) DK2640362T4 (OSRAM)
EA (2) EA025852B1 (OSRAM)
EC (2) ECSP13012700A (OSRAM)
ES (1) ES2524408T5 (OSRAM)
HK (1) HK1206592A1 (OSRAM)
HR (1) HRP20140946T1 (OSRAM)
IL (1) IL226300B (OSRAM)
MA (1) MA34735B1 (OSRAM)
ME (1) ME01980B (OSRAM)
MX (1) MX347512B (OSRAM)
MY (1) MY185604A (OSRAM)
NZ (1) NZ610729A (OSRAM)
PE (3) PE20170521A1 (OSRAM)
PH (1) PH12013501002A1 (OSRAM)
PL (1) PL2640362T5 (OSRAM)
PT (1) PT2640362E (OSRAM)
RS (1) RS53691B1 (OSRAM)
SG (3) SG190333A1 (OSRAM)
SM (1) SMT201400150B (OSRAM)
TW (1) TWI556840B (OSRAM)
UA (1) UA114075C2 (OSRAM)
WO (1) WO2012068535A1 (OSRAM)
ZA (1) ZA201304481B (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ540728A (en) 2003-01-14 2008-08-29 Gilead Sciences Inc Compositions and methods for combination antiviral therapy
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CA2818097C (en) 2010-11-19 2019-07-30 Janssen R & D Ireland Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
TWI516499B (zh) 2011-08-16 2016-01-11 吉李德科學股份有限公司 泰諾福韋（ｔｅｎｏｆｏｖｉｒ）亞拉芬醯胺（ａｌａｆｅｎａｍｉｄｅ）之半反式丁烯二酸鹽
CA2779052A1 (en) * 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
AU2013361401C1 (en) 2012-12-21 2018-08-09 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP2832351A1 (en) * 2013-07-29 2015-02-04 Sanovel Ilac Sanayi ve Ticaret A.S. Multilayer Tablet Formulations Comprising Tenofovir and Entecavir
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
CN118286245A (zh) 2014-12-26 2024-07-05 埃莫里大学 N4-羟基胞苷和衍生物及与其相关的抗病毒用途
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
KR20170003063A (ko) * 2015-06-30 2017-01-09 한미약품 주식회사 테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
CA2948021C (en) * 2015-11-09 2024-06-18 Gilead Sciences, Inc. Pharmaceutical formulations of (2r,5s,13 ar)-8hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzy1)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1'2':4,5]pyrazino [2,1-b][1,3] oxazepine-10-carboxamide
EP3439639A1 (en) * 2016-04-08 2019-02-13 Shionogi & Co., Ltd. Stabilized solid dosage form
TR201617448A2 (tr) * 2016-11-29 2018-06-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler
US10561614B2 (en) * 2017-01-27 2020-02-18 Steerlife India Private Limited Tenofovir granules
EP3645003A4 (en) * 2017-06-30 2021-03-10 VIIV Healthcare Company COMBINATION AND USES AND TREATMENTS THEREOF
US11331331B2 (en) 2017-12-07 2022-05-17 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CA3144534A1 (en) * 2019-07-03 2021-01-07 Janssen Sciences Ireland Unlimited Company Methods of treating hiv in pediatric patients with rilpivirine
CN112137981A (zh) * 2020-11-02 2020-12-29 成都晶富医药科技有限公司 富马酸丙酚替诺福韦片及其制备工艺
WO2024211882A1 (en) * 2023-04-07 2024-10-10 Navinta, Llc Stable compositions of rilpivirine hcl in combination with other anti-retroviral agents
CN119174735A (zh) * 2024-09-03 2024-12-24 安徽贝克生物制药有限公司 一种含利匹韦林的复方片及制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100965A (en) 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
EP1448170A4 (en) 2001-11-27 2010-05-12 Bristol Myers Squibb Co EFAVIRENZ STAMP PREPARATIONS HAVING UNIQUE BIOPHARMACEUTICAL CHARACTERISTICS
NZ540728A (en) 2003-01-14 2008-08-29 Gilead Sciences Inc Compositions and methods for combination antiviral therapy
CA2577288C (en) 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
MX2007002595A (es) 2004-09-02 2007-04-25 Janssen Pharmaceutica Nv Clorhidrato de 4-[[4-[[4- (2-cianoetenil)-2, 6-dimetilfenil] amino]-2- pirimidinil] amino] benzonitrilo.
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
CN101309675A (zh) 2005-10-14 2008-11-19 微量技术有限公司 口服剂量组合的药品包装
RU2008128424A (ru) 2005-12-14 2010-01-20 Сипла Лимитед (In) Фармацевтическая комбинация, включающая нуклеотидный и нуклеозидный ингибиторы обратной транскриптазы (такие как тенофовир и ламивудин) в различных частях дозы
LT2487163T (lt) * 2007-02-23 2016-10-25 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
US20080286344A1 (en) 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
WO2008140461A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
EP2160394A1 (en) 2007-05-22 2010-03-10 Ultimorphix Technologies B.v. Tenofovir disoproxil hemi-fumaric acid co-crystal
WO2009037449A1 (en) 2007-09-18 2009-03-26 Cipla Limited Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors
WO2009106960A2 (en) 2008-02-27 2009-09-03 Aurobindo Pharma Limited Stable compositions of lamivudine, tenofovir and efavirenz
BRPI0911871A8 (pt) 2008-05-02 2018-03-06 Gilead Sciences Inc uso de partículas veículo sólidas para melhorar a processabilidade de um agente farmacêutico
HRP20151009T1 (hr) 2009-02-06 2015-10-23 Gilead Sciences, Inc. Dvoslojna tableta koja sadrži elvitegravir, kobicistat, emtricitabin i tenofovir
BR112012006261B1 (pt) 2009-09-21 2021-12-21 Gilead Sciences, Inc Compostos análogos de 2'-flúor substituído carbanucleosídeo, composto útil para a preparação do mesmo, composição farmacêutica e uso dos compostos análogos de 2'-flúor substituído carbanucleosídeo
WO2011077100A1 (en) 2009-12-24 2011-06-30 Cipla Limited Antiretroviral composition
CA2818097C (en) 2010-11-19 2019-07-30 Janssen R & D Ireland Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate

Also Published As

Publication number Publication date
SG190333A1 (en) 2013-06-28
PE20170521A1 (es) 2017-05-27
ES2524408T3 (es) 2014-12-09
ME01980B (me) 2015-05-20
PL2640362T3 (pl) 2015-03-31
MY185604A (en) 2021-05-25
EP2826466A1 (en) 2015-01-21
IL226300B (en) 2019-05-30
RS53691B1 (sr) 2015-04-30
US10857102B2 (en) 2020-12-08
KR101923103B1 (ko) 2018-11-28
PL2640362T5 (pl) 2022-05-02
PH12013501002A1 (en) 2013-09-09
SG10201509521WA (en) 2015-12-30
ES2524408T5 (es) 2022-04-25
CA2818097A1 (en) 2012-05-24
UA114075C2 (xx) 2017-04-25
EA025852B1 (ru) 2017-02-28
AU2018202635A1 (en) 2018-05-10
HK1206592A1 (en) 2016-01-15
PE20140163A1 (es) 2014-02-08
WO2012068535A1 (en) 2012-05-24
SMT201400150B (it) 2015-01-15
SG10201912527XA (en) 2020-02-27
PE20211657A1 (es) 2021-08-24
AU2011329642A1 (en) 2013-05-02
JP2014500261A (ja) 2014-01-09
ZA201304481B (en) 2022-03-30
JP6138851B2 (ja) 2017-05-31
AU2016208417A1 (en) 2016-08-18
CN103491948B (zh) 2016-11-02
CN103491948A (zh) 2014-01-01
EA201390651A1 (ru) 2013-11-29
TWI556840B (zh) 2016-11-11
MX2013005669A (es) 2013-11-04
DK2640362T3 (en) 2014-12-01
HRP20140946T1 (hr) 2015-02-13
JP2015131853A (ja) 2015-07-23
MX347512B (es) 2017-04-28
AR123409A2 (es) 2022-11-30
KR20140037799A (ko) 2014-03-27
AP2013006931A0 (en) 2013-06-30
BR112013012245B1 (pt) 2022-09-27
EA201691695A1 (ru) 2017-11-30
EP2640362B2 (en) 2021-12-01
DK2640362T4 (da) 2022-03-07
ECSP19078196A (es) 2019-11-30
US20130243857A1 (en) 2013-09-19
NZ610729A (en) 2015-10-30
CR20130293A (es) 2013-10-03
AU2011329642B2 (en) 2016-08-11
CN106511357A (zh) 2017-03-22
TW201238612A (en) 2012-10-01
PT2640362E (pt) 2014-11-28
AP3816A (en) 2016-09-30
AU2016208417B2 (en) 2018-04-05
BR112013012245A2 (pt) 2016-08-09
AR084500A1 (es) 2013-05-22
MA34735B1 (fr) 2013-12-03
CA2818097C (en) 2019-07-30
HK1190064A1 (en) 2014-06-27
ECSP13012700A (es) 2013-08-30
EP2640362A1 (en) 2013-09-25
CO6761300A2 (es) 2013-09-30
EP2640362B1 (en) 2014-09-10

Similar Documents

Publication Publication Date Title
CL2013001402A1 (es) Un comprimido que comprende a) una primera capa comprendiendo rilpivirina hcl, sustancialmente exenta de fumarato de diisopropilo de tenofovir, b) una segunda capa comprendiendo fumarato de diisopropilo de tenofovir, sustancialmente exenta de rilpivirina hcl, y c) adicionalmente emtricitabina; y su uso para tratar una infeccion por vih.
CY2024017I1 (el) Συνδυασμοι δολουτεγραβιρης και λαμιβουδινης για την αγωγη λοιμωξης απο hiv
CL2014000370A1 (es) Hemifumarato de tenofovir alafenamida; metodo de preparación; composicion farmaceutica que lo comprende; metodo para preparar la composicion farmaceutica; y uso en el tratamiento de una infeccion por hiv.
CL2016002132A1 (es) Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo.
CL2013000424A1 (es) Forma de dosificacion farmaceutica resistente al rompimiento que comprende a) un ingrediente farmacologicamente activo, b) un polimero, c) un oxido de polialquileno, donde a) esta presente en una matriz de liberacion controlada que comprende b) y c).
CL2014003306A1 (es) Preparacion farmaceutica oral que comprende un inhibidor de tirosina quinasa de bruton y forma cristalina a del mismo.
SMT201500266B (it) Compresse a doppio strato comprendenti elvitegravir, cobicistat, emtricitabina e tenofovir
AP2011005944A0 (en) Inhibitors of human immunodeficiency virus replication.
CL2015001756A1 (es) Compuestos derivados de carbamoilpiridona policiclicos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion de vih en un humano que tiene o se encuentra en riesgo de tener la infeccion.
CL2014001585A1 (es) Compuestos derivados de betulina; composicion farmaceutica; y el uso de los mismos en el tratamiento y prevencion de una infeccion por vih.
CL2013003524A1 (es) Núcleo absorbente que comprende material absorbente con peso base que varía a través del núcleo y comprende una estructura absorbente que incluye una capa de sustrato y una capa absorbente con material absorbente; artículo absorbente desechable.
CL2013001398A1 (es) Articulo absorbente que comprende una lamina posterior que incluye una pelicula biodegradable y desechable; pelicula biodegradable y desechable; y estuche, envoltura o bolsa que comprende a dicha pelicula.
CL2013000718A1 (es) Un complejo de inclusion que comprende a) una ciclodextrina, b) fulvestrant y c) un portador; su metodo de preparacion; formulacion y forma de dosificacion que comprende al complejo; preparacion que comprende al complejo o a la formulación; y su uso en el tratamiento del cancer y lupus eritematoso sistemico, entre otras enfermedades.
HUE066402T2 (hu) A telomerázinhibitor imetelstat mieloproliferatív rendellenességek és mieloproliferatív neopláziák kezelésére
WO2011138040A3 (en) Vaccine against beta-herpesvirus infection and use thereof
CL2012003523A1 (es) Método para la preparación de una composición farmacéutica que contiene un portador de oxígeno termoestable; composicion farmaceutica que contiene un portador de oxigeno altamente purificado y termoestable.
WO2011144674A3 (en) PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD
IL243786A0 (en) A drug that contains a pharmaceutical combination of dolutegravir, emtricitabine and tenofovir
CL2013003229A1 (es) Compuestos inhibidores del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vhc.
BRPI1008887A2 (pt) peptídeos de foxm1 e vacinas contendo os mesmo
ES2425315R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria
ES2524385R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
CL2014001754A1 (es) Una preparacion farmaceutica que comprende 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona o una de sus sales y beta-ciclodextrina sustituida.
IT1399793B1 (it) Procedimento di preparazione di una biomassa comprendente plantaricina e suoi usi in campo medico.